Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie M Vose

Blood

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Blood|January 25, 2017
Angioimmunoblastic T-cell lymphoma: the many-faced lymphomaMatthew A Lunning, Julie M Vose
Blood|April 16, 2011
Peripheral T-cell lymphomaFrancine M Foss, Pier Luigi Zinzani, Julie M Vose, et al.
Blood|November 9, 2002
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survivalChristine P Hans, Dennis D Weisenburger, Julie M Vose, et al.
Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.
Blood|April 4, 2008
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma ProjectKerry J Savage, Nancy Lee Harris, Julie M Vose, et al.
Blood|January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaJonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.
Blood|March 5, 2004
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaAndres Forero, Paul L Weiden, Julie M Vose, et al.
Blood|December 13, 2017
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphomaAlex F Herrera, Alison J Moskowitz, Nancy L Bartlett, et al.
Blood|December 8, 2009
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaJonathan W Friedberg, Jeff Sharman, John Sweetenham, et al.
Blood|April 7, 2021
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study resultsRanjana H Advani, Alison J Moskowitz, Nancy L Bartlett, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Blood|January 25, 2017
Angioimmunoblastic T-cell lymphoma: the many-faced lymphomaMatthew A Lunning, Julie M Vose
Blood|April 16, 2011
Peripheral T-cell lymphomaFrancine M Foss, Pier Luigi Zinzani, Julie M Vose, et al.
Blood|November 9, 2002
A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survivalChristine P Hans, Dennis D Weisenburger, Julie M Vose, et al.
Blood|February 26, 2005
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomabJohn M Bennett, Mark S Kaminski, John P Leonard, et al.
Blood|April 4, 2008
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma ProjectKerry J Savage, Nancy Lee Harris, Julie M Vose, et al.
Blood|January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaJonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.
Blood|March 5, 2004
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphomaAndres Forero, Paul L Weiden, Julie M Vose, et al.
Blood|December 13, 2017
Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphomaAlex F Herrera, Alison J Moskowitz, Nancy L Bartlett, et al.
Blood|December 8, 2009
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaJonathan W Friedberg, Jeff Sharman, John Sweetenham, et al.
Blood|April 7, 2021
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study resultsRanjana H Advani, Alison J Moskowitz, Nancy L Bartlett, et al.
Pageof 3